ATE456364T1 - Virosomen-artige partikel - Google Patents

Virosomen-artige partikel

Info

Publication number
ATE456364T1
ATE456364T1 AT04710132T AT04710132T ATE456364T1 AT E456364 T1 ATE456364 T1 AT E456364T1 AT 04710132 T AT04710132 T AT 04710132T AT 04710132 T AT04710132 T AT 04710132T AT E456364 T1 ATE456364 T1 AT E456364T1
Authority
AT
Austria
Prior art keywords
virosome
viral envelope
particles
short
chain phospholipid
Prior art date
Application number
AT04710132T
Other languages
English (en)
Inventor
Anke Huckriede
Jonge Jorgen De
Antonius Stegmann
Pieter Schoen
Jan Wilschut
Original Assignee
Bestewil Holding Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32669007&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE456364(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bestewil Holding Bv filed Critical Bestewil Holding Bv
Application granted granted Critical
Publication of ATE456364T1 publication Critical patent/ATE456364T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36123—Virus like particles [VLP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT04710132T 2003-02-13 2004-02-11 Virosomen-artige partikel ATE456364T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03075422A EP1447080A1 (de) 2003-02-13 2003-02-13 Methode zur Herstellung von Virosomen-artigen Partikeln
PCT/NL2004/000101 WO2004071492A1 (en) 2003-02-13 2004-02-11 Virosome-like-particles

Publications (1)

Publication Number Publication Date
ATE456364T1 true ATE456364T1 (de) 2010-02-15

Family

ID=32669007

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04710132T ATE456364T1 (de) 2003-02-13 2004-02-11 Virosomen-artige partikel

Country Status (16)

Country Link
US (1) US7901920B2 (de)
EP (3) EP1447080A1 (de)
JP (1) JP4634997B2 (de)
KR (1) KR101026053B1 (de)
CN (1) CN100548275C (de)
AT (1) ATE456364T1 (de)
AU (1) AU2004211869B2 (de)
BR (1) BRPI0407433A (de)
CA (1) CA2515392C (de)
DE (1) DE602004025327D1 (de)
DK (1) DK1594466T3 (de)
ES (1) ES2340163T3 (de)
NZ (1) NZ541708A (de)
PT (1) PT1594466E (de)
SI (1) SI1594466T1 (de)
WO (1) WO2004071492A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1666056A1 (de) * 2004-12-06 2006-06-07 Bestewil Holding B.V. Krebsimpfstoffvesikeln
US8535683B2 (en) * 2006-03-22 2013-09-17 Abbott Biologicals B.V. Intranasal or inhalational administration of virosomes
AR059972A1 (es) * 2006-03-22 2008-05-14 Solvay Pharm Bv Administracion intranasal o inhalacional de virosomas
EP1938835A1 (de) * 2006-12-29 2008-07-02 Pevion Biotech AG Nichtspezifische immunostimulierende Wirkstoffe
EP2014279A1 (de) 2007-06-22 2009-01-14 Pevion Biotech AG Virosomen enthaltend Haemagglutinin, das von über Zelllinien hergestellten Influenza-Viren stammt, Zusammensetzungen, Herstellungsverfahren, Verwendung davon
EP2058002A1 (de) 2007-10-31 2009-05-13 Bestewil Holding B.V. Rekonstituierte Virushüllen des Respiratory Syncytial Virus und Anwendung als Impfstoff für Respiratory Syncytial Virus
CA2742955A1 (en) * 2008-11-06 2010-05-14 University Of Washington Bispecific intracellular delivery vehicles
US20110262415A1 (en) * 2008-12-21 2011-10-27 Cnr - Consiglio Nazionale Delle Ricerche Erythrocyte-based delivery system, method of preparation and uses thereof
CN102365095B (zh) 2009-02-06 2015-11-25 麦米提斯公司 分裂gp41
US8765137B2 (en) 2009-02-06 2014-07-01 Mymetics Corporation Gp41 antigens
WO2011128720A1 (en) 2010-04-14 2011-10-20 Mymetics Corporation Trans-activator of transcription protein
EP2646107A2 (de) 2010-12-01 2013-10-09 Spinal Modulation Inc. Wirkstofffreisetzungssysteme für selektive nervenmodulation
US20160151479A1 (en) 2013-07-02 2016-06-02 Crucell Holland B.V. Method for preparing virosomes
WO2015000831A1 (en) 2013-07-02 2015-01-08 Crucell Holland B.V. Method for preparing virosomes
WO2016039619A1 (en) 2014-09-12 2016-03-17 Bestewil Holding B.V. Methods for providing adjuvanted virosomes and adjuvanted virosomes obtainable thereby
WO2016039620A2 (en) 2014-09-12 2016-03-17 Bestewil Holding B.V. Respiratory syncytial virus virosomes
US20190105381A1 (en) * 2016-03-16 2019-04-11 Institut Curie Method for preparing viral particles with cyclic dinucleotide and use of said particles for treating cancer
US11523988B2 (en) 2018-11-29 2022-12-13 Catalent U.K. Swindon Zydis Limited Oral dispersible vaccine comprising virosomes
WO2020121062A1 (en) 2018-12-12 2020-06-18 Anergis S.A. Methods of improving efficacy of allergy vaccines
JP7072604B2 (ja) * 2020-06-23 2022-05-20 アンスティテュ・クリー 環状ジヌクレオチドを含むウイルス粒子を調製する方法及びがんを治療するための前記粒子の使用
CN115337404A (zh) * 2021-05-12 2022-11-15 中国医学科学院基础医学研究所 细胞微颗粒在治疗呼吸道病毒性肺炎上的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0231039B1 (de) 1986-01-14 1992-01-08 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Verfahren zur Herstellung immunologischer Komplexe und diese enthaltende pharmazeutische Zusammensetzung
NZ224422A (en) 1987-05-05 1990-11-27 Molecular Eng Ass Composition adapted for intranasal immunisation against viral infection comprising a glycoprotein complexed with a lipid
US5252348A (en) * 1990-10-19 1993-10-12 Univ. Of Florida Research Foundation, Inc. Artificial viral envelopes
EP0555333B1 (de) 1990-10-19 1995-12-27 University Of Florida Künstliche virushüllen
PL296382A1 (en) * 1991-02-02 1993-11-02 Nika Health Products Ltd Li Li Artificial membrane beads containing functionally active peptides responsible for fusion as a drug administering system
AU655823B2 (en) 1991-05-08 1995-01-12 Crucell Switzerland Ag Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them
US5980898A (en) * 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
ES2288886T3 (es) * 1999-12-30 2008-02-01 Dana-Farber Cancer Institute, Inc. Proteoliposomas que contienen una proteina integral de membrana que tiene uno o mas dominios transmembrana.
ATE331530T1 (de) 2000-02-15 2006-07-15 Id Biomedical Corp Quebec Proteasom-influenzavirus-impfstoffzusammensetzu g

Also Published As

Publication number Publication date
SI1594466T1 (sl) 2010-05-31
KR20050105468A (ko) 2005-11-04
WO2004071492A1 (en) 2004-08-26
EP2255789A1 (de) 2010-12-01
JP2006517582A (ja) 2006-07-27
CA2515392A1 (en) 2004-08-26
AU2004211869B2 (en) 2008-07-03
EP1594466A1 (de) 2005-11-16
CA2515392C (en) 2012-01-03
US20060228376A1 (en) 2006-10-12
CN100548275C (zh) 2009-10-14
CN1750812A (zh) 2006-03-22
DK1594466T3 (da) 2010-05-25
EP1447080A1 (de) 2004-08-18
PT1594466E (pt) 2010-04-15
NZ541708A (en) 2008-06-30
ES2340163T3 (es) 2010-05-31
JP4634997B2 (ja) 2011-02-16
KR101026053B1 (ko) 2011-04-04
US7901920B2 (en) 2011-03-08
AU2004211869A1 (en) 2004-08-26
DE602004025327D1 (de) 2010-03-18
BRPI0407433A (pt) 2006-01-24
EP1594466B1 (de) 2010-01-27

Similar Documents

Publication Publication Date Title
ATE456364T1 (de) Virosomen-artige partikel
DK1780269T3 (da) Virusrensningsmetoder
TW200700401A (en) Process for preparing an epoxide starting from a chlorohydrin
DE602005015174D1 (de) Verfahren zur herstellung von montelukast-natrium
DE602004029724D1 (de) Verfahren zur Herstellung von organischen Verbindungen aus Glycerol, stammend aus nachwachsenden Rohstoffen
ATE478082T1 (de) Phosphonate, monophosphonamidate, bisphosphonamidate zur behandlung von virenerkrankungen
ATE306252T1 (de) Verfahren zur herstellung kristalliner partikel zur inhalation
UA99896C2 (uk) Спосіб одержання глюкопіранозилзаміщених похідних бензилбензолу, проміжні продукти та способи їх одержання
DE502006001783D1 (de) Verfahren zur herstellung von silicium aus halogensilanen
EA200500920A1 (ru) Стабильный пенистый крем
NO20085153L (no) Fusjonerte bisykloheterosykelsubstituerte azabisykliske alkanderivater
DK1623634T3 (da) Fremgangsmåde til fremstilling af regenereret tobaksmateriale
SG10201408106WA (en) Purification of vwf for increased removal of non-lipid enveloped viruses
ATE524481T1 (de) Verfahren zur herstellung von (mercaptoorganyl)alkylpolyethersilanen
MX2015007093A (es) Composiciones y metodos para el tratamiento de canceres cerebrales.
NO20074047L (no) Ny fremgangsmate for fremstilling av substituerte indoler
IL179929A0 (en) Method for producing (z) - 1 - phenyl - 1 - diethylaminocarbonyl - 2 - aminomethyl cyclopropane hydrochloride
DE50108846D1 (de) Verfahren zur Herstellung von Ethanbis(methylphosphinsäure)
ATE518828T1 (de) Ein-topf-verfahren zur herstellung von 3-(2,2,2- trimethylhydrazinium)propionat-dihydrat
WO2003060088A3 (en) Viral vaccine production method
FI20061134A (fi) Menetelmä tasaisen tiheydeltään alhaisen kartongin valmistamiseksi
DE502005006745D1 (de) Herstellung von doppelzigaretten mit aussen liegenden filtern
EA200101193A1 (ru) Сигарета с табачным фильтром
DE60103560D1 (de) Prozess zur herstellung von paclitaxel
DE602006020760D1 (de) Verfahren zur herstellung von perindoprilerbumin

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1594466

Country of ref document: EP